Posters

      Impact of Switching to a Heat-Not-Burn Tobacco Product on CYP1A2 Activity: A Review of Four Clinical Studies

      van der Plas, A.; Blanc, N.; Haziza, C.; Titz, B.; Taranu, B.; Ciuria, N.; Ciprietti, S.; Witt-Gonzalez, C.; Ancin, D.; Riccitelli, V.; D'Errico, I.; Pietro, M.; Prieto, L.; Weitkunat, R.; Ivanov, N.; Lüdicke, F.

      Conference date
      Feb 22, 2019
      Conference name
      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Polycyclic aromatic hydrocarbons (PAH) are products of incomplete combustion of organic matter through tobacco smoking and are well-known inducers of drug-metabolizing enzymes. Exposure to PAHs in humans results in marked induction of cytochrome CYP1A2. For instance, the average clearance rates of caffeine, chlorpromazine, clozapine, haloperidol, olanzapine, and theophylline increase by 30–100% in smokers compared with nonsmokers. Switching to novel tobacco products that reduce the exposure to harmful and potentially harmful constituents, including PAHs, could reduce CYP1A2 activity compared with that of continuing smoking. This would mean that, smokers taking medications that are primarily metabolized by this enzyme will have higher systemic clearance due to increased enzyme induction. The aim of this review is to summarize the evidence from clinical studies on the effects of switching to a heat-not-burn tobacco product (IQOS® with HEETS®) on CYP1A2 activity and to review the corresponding potential effects on drugs primarily metabolized by CYP1A2. Four clinical studies that are part of the clinical assessment of IQOS with HEETS looked at CYP1A2 activity by measuring the caffeine metabolic ratio (CMR) in plasma in switchers to IQOS with HEETS and those who continued smoking or abstained from smoking. Results showed that after five days of exclusive IQOS with HEETS use, CMR levels were significantly decreased to an extent similar to that of smoking abstinence in all clinical studies, with a difference of IQOS with HEETS vs. cigarette smoking between 21.7% and 37%. The CMR levels remained decreased in IQOS with HEETS users in one study (ratio of 72.1% at Day 5 and 70.4% at Day 90) while the effect was partially diluted in the other one (ratio of 63.0% at Day 5 and 77.1% at Day 90) which may be explained by the concomitant cigarette smoking during the ambulatory period. The observed reduction in CYP1A2 activity when using IQOS with HEETS, comparable to that seen in smoking abstinence, suggests that monitoring smokers using medications primarily metabolized by CYP1A2 with a narrow therapeutic margin may be recommended upon switching to IQOS with HEETS.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.